Insmed | INSM - Capitale Ordinario





Capitale Ordinario Cambiamento Data
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Cytokinetics USD 124.43M 2.17M 2026-03
DBV Technologies USD 235.6M 98.78M 2025-12
Gilead Sciences USD 1.24B 1000K 2026-06
Heron Therapeutics USD 188.31M 4.99M 2025-12
Insmed USD 218.28M 1.76M 2026-06
Novartis USD 1.91B 60K 2026-03
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Sarepta Therapeutics USD 105.62M 53K 2026-06
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 253.3M 900K 2026-06